{"acquisitions":[],"changes":[],"country":"DK","description":"Damora Therapeutics (formerly Galecto) develops DMR-001, a subcutaneous monoclonal antibody targeting mutant calreticulin that drives essential thrombocythemia and myelofibrosis. It treats 42,000 US patients with mutCALR-driven MPNs. DMR-001 shows 10x potency versus reference antibodies and a 5x half-life extension.","domain":"galecto.com","employees":null,"founded":2011,"fundingTotalQuarantined":false,"githubOrg":"galecto","githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":55.686724,"lng":12.570072,"location":"Copenhagen, Denmark","multiples":[],"name":"Galecto","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":259200000,"connectionsAmong":[],"currency":"EUR","date":"2025-06-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"galecto-com-2025-06-01-private-placement","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"galecto-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"galecto.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://galecto.com"},{"fact":"description","publisher":"galecto.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://galecto.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Cloudflare","Netlify","Typekit","Adobe Fonts","Next.js","React","Webpack"],"totalRaisedUsd":281880000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}